APM - Aptorum Group soars 10% on positive interim Phase I data on ALS-4 and progress on SACT-1

Aptorum Group (APM) gains 10% premarket after announcing progress in respect of its ongoing Phase I clinical trial for ALS-4 and Pre-IND preparation for SACT-1, a repurposed small molecule targeting neuroblastoma. ALS-4’s first-in-human Phase I trial is single and multiple ascending dose study designed to evaluate safety, tolerability, and pharmacokinetics of orally administered ALS-4 in healthy male and female adult volunteers.Dosing and safety reviews of Cohort A (25mg) and Cohort B (50mg) have been completed and eight subjects (6 received ALS-4 and 2 received placebo) were dosed in each cohort.The company announces that no human subjects dropped out of the studies and no serious adverse events ((SAE)) were reported.In addition, no relevant clinical changes in respect of vital signs, ECG, clinical laboratory test results and physical examinations were observed compared to the relevant baseline.On this basis, the remaining ALS-4 Phase I study will continue to progress and as of this date, Cohort C (100mg)

For further details see:

Aptorum Group soars 10% on "positive" interim Phase I data on ALS-4 and progress on SACT-1